Your QRM Program Looks Great on Paper. Here Is Why That Is the Problem for Pharma Quality Leaders

There is a particular kind of frustration that quality leaders in pharma know well. You have done the work. Your team has developed risk matrices, maintained risk registers, and documented a Quality Risk Management (QRM) program, the structured approach to identifying, evaluating, and controlling risks that could affect product quality and patient safety, that references all the right guidelines. When a regulatory inspector asks to see your QRM documentation, it is ready and it is thorough.

And then, somewhere on the manufacturing floor, a quality event occurs that your QRM program should have caught. And when you trace it back, you find that no structured risk thinking ever entered the process at the moment it was needed most.

That disconnect, between a QRM program that exists and one that actually works, is one of the most persistent challenges in pharmaceutical manufacturing today. And it is getting harder to ignore.

The Guideline Got Updated. The Execution Problem Did Not.

The International Council for Harmonisation (ICH) Guideline Q9, the industry's foundational framework for quality risk management in pharmaceutical development and manufacturing, has been in place since 2005. Its first major revision, ICH Q9(R1), was adopted in January 2023 and its supporting training materials were fully refreshed in early 2026.

The revision addressed something quality leaders had long identified as the real obstacle: subjectivity. Different people on the same team assess the same risk differently. Different sites apply the same QRM Standard Operating Procedure (SOP) with different levels of rigor. The same deviation gets a formal risk assessment at one facility and a quick close-out at another.

ICH Q9(R1) explicitly acknowledged that achieving a shared understanding of the application of risk management among diverse stakeholders is difficult because each stakeholder might perceive different potential harms, place a different probability on each harm occurring, and attribute different severities to each harm, and that this subjectivity can directly impact the effectiveness of risk management activities and the decisions made.

In other words, the guideline confirmed what quality leaders already knew: the inconsistency is real, it is significant, and it has consequences. What the guideline cannot do is fix it. That part is up to the organization and increasingly, up to the systems the organization chooses to rely on.

Why Regulatory Shifts Make This More Urgent

The regulatory environment has shifted considerably in recent years, and the pressure on QRM execution has grown accordingly.

Remote Regulatory Assessments (RRAs), virtual inspections conducted by regulatory authorities, have evolved from a pandemic-era necessity to a permanent oversight tool.

The United States Food and Drug Administration (FDA), which oversees pharmaceutical manufacturing compliance in the US, has officially designated RRAs as a core part of its inspection program. That means pharmaceutical manufacturers can no longer treat inspection readiness as something to prepare for when a notice arrives. The standard is continuous readiness, and the evidence needs to be in the system, not assembled after the fact.

FDA inspectors are now equipped with AI-powered analytical tools capable of identifying patterns and anomalies faster than traditional review methods. When an inspector can surface trends in your quality event data more quickly than your own team can, the risk of an undetected systemic pattern becoming a regulatory finding increases significantly.

Against this backdrop, a QRM program that lives primarily in documents and gets activated episodically: during inspections, at product launches, when a Corrective and Preventive Action (CAPA) is not just inefficient. It is a growing liability.

What the Gap Looks Like on the Floor

The execution gap shows up in specific, recognizable patterns. If you oversee quality across multiple sites or a complex manufacturing network, at least one of these will feel familiar.

Two Sites, Two Outcomes

A deviation is logged at a facility. A structured risk assessment follows, a CAPA is initiated, and the investigation is thorough. A month later, the same category of deviation surfaces at another site. It is closed with a brief description and a sign-off, because nothing in the workflow required anything more rigorous.

Change Control Without Risk

A change request moves through its approval routing correctly. Everyone does their part. But no risk evaluation was linked to the specific process parameters, raw materials, or equipment being modified because the workflow did not structurally require one. The change goes live. The risk question was never formally asked.

The Out-of-Specification (OOS) Result That Created Undocumented Risk

An OOS result escalates from a Phase 1 to a Phase 2 investigation. The teams handle it competently. But the risk to impacted batches downstream is discussed informally, over email, outside the investigation record. No one captured it. No one can reference it later.

The Finding That Keeps Coming Back

An audit surfaces a recurring issue. Quality leadership wants to know whether it is a systemic pattern or an isolated gap. Without connected risk data, there is no clean answer, until a regulatory inspector draws the connection first.

None of these scenarios represent a failure of competence or commitment. They represent a failure of infrastructure. The people involved did what the system asked of them. The system just did not ask for enough.

What Risk-Based Thinking Looks Like When It Is Actually Working

The operational version of QRM is not complicated to describe. It means that every quality decision comes with a risk input built in, not as a separate step that gets added when time permits, but as a structural requirement of the workflow itself.

Here is what that looks like across the four quality processes where it matters most:

• Deviation Management: When a deviation is logged, the workflow immediately prompts a structured risk assessment. Severity, probability, and detectability: the three factors used to evaluate how serious a risk is, are captured in the same record. Escalation thresholds are set in advance, so the system routes the right deviations to the right people without relying on someone's memory or judgment in the moment.
• Change Control: Every change request includes a risk evaluation tied to the specific elements being modified: process steps, raw materials, equipment, or procedures. That evaluation shapes approval routing, testing requirements, and how the change is monitored after implementation. Not as an optional supplement, but as a required part of the record.
• OOS Investigations: Risk assessment is embedded in the lab investigation record. When a result escalates from Phase 1 to Phase 2, the risk implications for impacted batches sit inside the record, visible to every stakeholder involved, traceable, and ready for review at any time.
• Audit findings: When a recurring finding surfaces, quality leadership can immediately pull up its full risk history, not to explain it to an inspector, but to make a proactive, informed decision about what it signals and what should happen next.

When QRM works this way, risk is not a parallel function. It is woven into the quality work that is already happening. The question stops being "did we do a risk assessment?" and becomes "what did the risk assessment tell us?"

The Document Cannot Do What the System Can

Most pharma quality organizations have the right intent. The QRM SOP is written. The training is completed. The awareness is there. What frequently breaks down is the step between intent and consistent execution - particularly across multiple sites, multiple shifts, and large manufacturing networks.

Legacy paper-based systems and disconnected digital tools are no longer sufficient to meet the demands of modern pharma quality management. Regulatory agencies expect real-time visibility, rapid response capabilities, and comprehensive audit trails - requirements that manual processes simply cannot deliver at scale.

A SOP tells people what to do. It cannot make them do it consistently when the pressure is on, the shift is short-staffed, or the process is moving fast. A connected Enterprise Quality Management System (EQMS), a unified digital platform that manages quality processes, records, and data across an organization - can, because it makes the right action the path of least resistance. Risk assessment becomes the thing that happens automatically when a deviation is logged, not the thing someone remembers to add afterward.

Proactive quality, in operational terms, means the risk signal surfaces before the event escalates, not because someone was paying close attention, but because the system was designed to surface it.

Putting It Into Practice

ComplianceQuest's Risk Management Solution provides a centralized risk repository and structured workflows for risk identification, evaluation, mitigation, and monitoring, producing risk records, assessments, mitigation plans, and dashboards aligned with ISO 31000, ISO 14971, and ICH Q9.

It has integrated capabilities that work together to make risk management a functioning part of daily quality operations:

• Risk Register: A centralized repository of identified risks at the project, department, or company level, with advanced analytics and hierarchical structures that help quality teams drive strategic decisions on potential threats.
• Risk Audit: Ongoing monitoring and evaluation of risk and compliance weaknesses across the organisation, with audit planning, scheduling, report generation, and AI-powered risk categorization that helps surface issues earlier.
• Process Inspections: Risk assessments can be launched from anywhere within the platform, using AI and analytics to spot potential risks based on historical and trending data, giving teams a forward-looking picture rather than a rear-view record of what has already happened.

What makes this operationally useful rather than simply another compliance layer is how risk records are created. Risks are launched directly from audits, CAPAs, changes, complaints, and nonconformances, making risk assessment a natural part of the quality workflow, not a separate task that requires a separate system and a separate conversation.

Risk work shifts from reactive to proactive through thresholds, analytics, and integrated launches from quality processes, with linked data and monitoring so leadership can prioritize mitigation before issues escalate.

The practical outcome of that shift is what quality leaders describe when they talk about moving from reactive firefighting to genuine quality governance.

When risk is built into every quality workflow by design, the QRM program stops being something you demonstrate to an inspector and starts being something that actually shapes outcomes every day.

Key Takeaways

• ICH Q9(R1) identified the right problem. Subjectivity in risk assessment is the core execution challenge, and it cannot be resolved by awareness alone.
• The 2026 regulatory environment raises the stakes. AI-assisted inspections and permanent RRAs mean QRM inconsistencies are harder to conceal and easier for regulators to identify.
• The execution gap is a systems problem, not a people problem. Individual competence cannot substitute for infrastructure that enforces risk-based thinking as a standard part of every quality decision.
• Risk assessment belongs inside the workflow, not beside it. Deviation management, change control, OOS investigations, and audit findings are the moments where risk must be required, not recommended.
• The shift from reactive to proactive quality requires design, not intention. When a connected EQMS makes risk assessment the default, quality organizations stop discovering risk after the fact and start managing it before it matters.